EE51 Cost-Effectiveness of Esketamine Nasal Spray Compared to Intravenous Ketamine for Patients with Treatment-Resistant Depression in the US Utilizing Clinical Trial Efficacy and Real-World Effectiveness Estimates
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.305
https://www.valueinhealthjournal.com/article/S1098-3015(22)00506-X/fulltext
Title :
EE51 Cost-Effectiveness of Esketamine Nasal Spray Compared to Intravenous Ketamine for Patients with Treatment-Resistant Depression in the US Utilizing Clinical Trial Efficacy and Real-World Effectiveness Estimates
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00506-X&doi=10.1016/j.jval.2022.04.305
First page :
Section Title :
Open access? :
No
Section Order :
10267